骨样骨瘤的无创治疗:MR引导高强度聚焦超声的前瞻性开发研究
这项前瞻性研究纳入50例临床与影像诊断为非脊柱骨样骨瘤的儿童及年轻成人,45例接受MR引导高强度聚焦超声治疗。中位VAS疼痛评分从治疗前8降至1周及1、6、12、24、36个月随访时的0,39例(87%)在3年观察期内维持VAS 0分;36个月随访时42例仅接受该治疗的患者中32例(76%)MR显示无残留瘤巢血供。
要点
- MR引导高强度聚焦超声治疗后中位VAS疼痛评分由8降至0,并维持至36个月随访。
- 45例中39例(87%)在3年观察期内达到并维持VAS评分0分。
- 36个月随访时42例仅接受该治疗者中32例(76%)MR显示无残留瘤巢血供。
核心结论
- MR引导高强度聚焦超声显示出持久的临床疗效与安全性,这些特征提示其有潜力成为骨样骨瘤常规治疗策略的一部分。
研究设计与样本
- 前瞻性开发研究,经机构审查委员会批准并在clinicaltrials.gov注册(注册号NCT02302651),2010年6月至2013年6月纳入50例临床与影像诊断为非脊柱骨样骨瘤且无MR引导高强度聚焦超声禁忌证的患者,45例接受治疗,按方案分析。
关键影像表现/征象
- 36个月随访时,MR成像显示42例仅接受MR引导高强度聚焦超声治疗的患者中32例(76%)无残留瘤巢血管化。
诊断标准与关键数值
- 中位VAS疼痛评分(0-10分)从治疗前8降至1周及1、6、12、24、36个月随访时的0。
- 疼痛对睡眠及身体和日常活动干扰程度的中位VAS评分在治疗后第1个月内降至0,并在后续随访中保持稳定。
- FACT-BP评分(0-60分)中位数从治疗前28升至1周随访时55、6个月及后续随访时60。
- 45例中39例(87%)在3年观察期内达到并维持VAS评分0分。
临床应用与阅片要点
- 治疗后以VAS疼痛评分和FACT-BP评分随访评估疗效,疼痛评分可在1周内降至0。
- 36个月随访时以MR成像评估瘤巢血管化情况,本研究中42例仅接受该治疗者中32例(76%)无残留瘤巢血管化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To demonstrate that magnetic resonance (MR) imaging-guided high-intensity focused ultrasound (HIFU) is a safe, effective, and durable treatment option for the management of osteoid osteoma in children and young adults. Materials and Methods This prospective study was institutional review board approved and is registered with clinicaltrials.gov (identification number NCT02302651). Written informed consent was obtained from patients or their parents. Patients who had both clinical and radiologic findings that were diagnostic for nonvertebral osteoid osteoma and no contraindications to MR imaging-guided HIFU were enrolled between June 2010 and June 2013. The feasibility, safety, and clinical effectiveness of MR imaging-guided HIFU were considered primary outcomes; tumor control at imaging was considered a secondary outcome. Analyses were conducted on a per-protocol basis. Results Forty-five of the 50 recruited patients underwent MR imaging-guided HIFU. All patients were discharged without treatment-related complications. The median visual analog scale (VAS) pain score (scale, 0-10) decreased from 8 before treatment to 0 at 1-week and 1- , 6- , 12- , 24- , and 36-month follow-up. Similarly, median VAS scores for the degree to which pain interfered with sleep and physical and daily activities decreased to 0 within the 1st month after treatment and remained stable at subsequent follow-up. Overall, 39 (87%) of the 45 patients achieved and maintained a VAS score of 0 during the 3-year observation period. Quality of life, as assessed by using Functional Assessment of Cancer Therapy-Bone Pain (FACT-BP) scores (scale, 0-60 points), improved, with the median FACT-BP score of 28 (points) before treatment increasing to a median score of 55 at 1-week follow-up and 60 at 6-month and subsequent follow-ups. At (final) 36-month follow-up, MR imaging depicted an absence of residual nidus vascularity in 32 (76%) of the 42 patients who were treated with MR imaging-guided HIFU only. Conclusion The durable clinical efficacy and safety of MR imaging-guided HIFU were demonstrated. These features are evidence of the potential of MR imaging-guided HIFU to be part of a routine strategy for the treatment of osteoid osteoma. © RSNA, 2017.
引用
- Napoli A, Bazzocchi A, Scipione R, et al. Noninvasive Therapy for Osteoid Osteoma: A Prospective Developmental Study with MR Imaging-guided High-Intensity Focused Ultrasound. Radiology. 2017. PMID: 28590796. doi:10.1148/radiol.2017162680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。